Building a Urologic Registry Using Circulating Tumor DNA to Improve Diagnosis and Treatment Monitoring in Patients With Prostate, Kidney, Bladder, or Ureter Cancer

What this Trial Is About

Urological cancers such as prostate, renal cell, bladder, and ureter cancers are increasing in the Korean population due to aging and lifestyle changes. Researchers are studying the use of circulating tumor DNA found in plasma and urine to help diagnose these cancers, monitor their progression, and evaluate treatment responses. The study also aims to build a large database of circulating tumor DNA profiles for these cancers in Korean patients and develop an optimized testing platform. The study involves patients diagnosed with one of the four urological cancers who have undergone surgery specific to their cancer type, such as prostatectomy, nephrectomy, cystectomy, or ureterectomy. Blood and urine samples will be collected to analyze circulating tumor DNA, which will be compared with genetic mutations found in the removed tumor tissue. The study will monitor these patients for up to 10 years after surgery to observe correlations between circulating tumor DNA and early diagnosis or prognosis. Participants will provide consent to use their medical and genetic information for the study and will be followed regularly to collect plasma and urine samples. Researchers will assess the relationship between circulating tumor DNA and tumor genetics shortly after surgery and over the long term. This observational study does not involve treatment interventions but focuses on collecting data to improve personalized medicine approaches for urological cancers.

Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA